1. Home
  2. WEYS vs PLX Comparison

WEYS vs PLX Comparison

Compare WEYS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyco Group Inc.

WEYS

Weyco Group Inc.

HOLD

Current Price

$31.86

Market Cap

280.9M

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.89

Market Cap

230.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEYS
PLX
Founded
1906
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
230.0M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
WEYS
PLX
Price
$31.86
$2.89
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$12.00
AVG Volume (30 Days)
4.7K
1.7M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.33%
N/A
EPS Growth
N/A
N/A
EPS
1.50
N/A
Revenue
$290,290,000.00
$53,399,000.00
Revenue This Year
N/A
$9.67
Revenue Next Year
N/A
$23.86
P/E Ratio
$21.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.51
$1.34
52 Week High
$34.63
$3.19

Technical Indicators

Market Signals
Indicator
WEYS
PLX
Relative Strength Index (RSI) 56.42 55.89
Support Level $31.06 $1.39
Resistance Level $33.40 $3.03
Average True Range (ATR) 0.81 0.15
MACD 0.04 -0.05
Stochastic Oscillator 74.19 30.12

Price Performance

Historical Comparison
WEYS
PLX

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: